No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 39 of the 40 quarters in the window, leaving 1 comparable quarter; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for DiaMedica Therapeutics Inc. (DMAC) stock was $8.42 as of Oct 5, 2026, 4:00 PM EDT, up 2.31% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +19.0% · 3-year avg +53.9%/yr · 5-year avg +16.4%/yr
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders.
Biotechnology · Minneapolis, MN
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.20
Revenue Est.
$13.50M
Last Quarter Results
EPS
$-0.19
vs Estimate
$-0.20
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DMAC | $453.70M | $8.42 | +2.31% | +19.00% | +16.41% | +7.89% | N/A |
| 2ASMB | $450.64M | $22.74 | +0.89% | -2.48% | -10.66% | -13.41% | vs DMAC |
| 3CAPR | $447.43M | $7.78 | -13.07% | -0.39% | +15.17% | -13.84% | vs DMAC |
| 4KMDA | $461.55M | $8.00 | -3.73% | +23.24% | +10.36% | +5.44% | vs DMAC |
| 5NRC | $468.31M | $20.78 | +2.11% | +75.54% | -11.49% | +4.93% | vs DMAC |
| 6CERS | $471.57M | $2.34 | +2.63% | +48.76% | -17.30% | -9.37% | vs DMAC |
forward FY estimate
N/A
$0.00
vs Estimate
$13.50M
Consensus Rating
Based on 4 analysts
Average Price Target
$15.50
+84.1% upside
Low
$11.00
Current
$8.42
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.21 | $-0.21 | $-0.21 | 2 |
| Quarter ending Dec 2026 | $-0.22 | $-0.22 | $-0.22 | 2 |
| Quarter ending Mar 2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Quarter ending Jun 2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.81 | $-0.77 | $-0.73 | 3 |
| FY 2027 | $-0.90 | $-0.75 | $-0.59 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $13.50M | $13.50M | $13.50M | 1 |
| Quarter ending Dec 2026 | $13.50M | $13.50M | $13.50M | 1 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $54.00M | $54.00M | $54.00M | 5 |
| FY 2027 | $2.22M | $2.22M | $2.22M | 3 |
